Maria J. de Miguel - Concepedia

Author

Maria J. de Miguel

Hospital Universitario HM Sanchinarro ORCID

Also Known As

Jianying Zhou, M De Miguel, M J De Miguel Luken, M. De Miguel, M. Miguel, M. de Miguel, M.J. De Miguel, M.J. De Miguel Luken, M.J. Miguel, M.J. de Miguel

268

Publications

3.3K

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario HM Sanchinarro Vall d'Hebron Institute of Oncology Vall d'Hebron Hospital Universitari Hospital Universitario Virgen del Rocío Institut Gustave Roussy

About

Maria J. de Miguel is an author at Hospital Universitario HM Sanchinarro specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	21	729
2	Cell Biology	3	3	131
3	Health Sciences	2	2	53
4	Public Health	1	1	15
5	Biochemistry	1	1	98

Maria J. de Miguel

Publications

Citations

H-Index

Page 1

	Year	Citations
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C Mutation Adrian G. Sacher, Patricia LoRusso, Manish R. Patel, New England Journal of Medicine	2023	256
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors Timothy A. Yap, Brent O’Carrigan, Marina S. Penney, Journal of Clinical Oncology	2020	237
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody James J. Harding, Víctor Moreno, Yung‐Jue Bang, Clinical Cancer Research	2021	155
MicroRNA clusters: dysregulation in lung adenocarcinoma and COPD Sonia Molina‐Pinelo, María Dolores Pastor, Rocío Aguilar Suárez, European Respiratory Journal AsthmaMirna ClusterInflammatory Lung DiseaseMedicineLung Adenocarcinoma	2014	106
Synthesis of phosphatidylcholine, a typical eukaryotic phospholipid, is necessary for full virulence of the intracellular bacterial parasite Brucella abortus Raquel Conde-Álvarez, María Jesús Grilló, Suzana P. Salcedo, Cellular Microbiology Full VirulenceBacteriologyBacteriophageDouble Mutant BapcspmtaBrucella Virulence	2006	98
A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies Dejan Juric, Johann S. de Bono, Patricia LoRusso, Clinical Cancer Research	2017	89
A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer Elena Garralda, Ammar Sukari, Nehal J. Lakhani, ESMO Open	2022	83
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study Bob T. Li, Funda Meric‐Bernstam, Aditya Bardia, The Lancet Oncology Breast OncologyMedicineSolid TumoursPathologyBreast Cancer	2024	82
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors Tae Won Kim, Howard A. Burris, Maria J. de Miguel, Clinical Cancer Research	2022	79
Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study Christina Guo, Maxime Chénard-Poirier, Desamparados Roda, The Lancet Oncology Hematological MalignancyMedicinePharmacologyCancer Cell BiologyMultiple Myeloma	2020	68

Page 1